CAMBRIDGE, Mass.—Genzyme Corp. today announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term
Jan. 19, 2011—BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701,
January 1, 2011
2010 AMDA Research Grant Awarded to Dr. Andrea Amalfitano
In 2010 the AMDA solicited grant applications from researchers around the world. After careful consideration and consultation with our Scientific
December 13, 2010
BMN-701: Potentially More Effective Treatment Option For Pompe
Webinar Details Title: BMN-701: Potentially more effective treatment option for Pompe Date: Monday, December 13, 2010 Speaker: Barbara Wuebbels, BioMarinJon
Webinar Details Title: Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV-GAA) Gene Vector in Patients With Pompe Disease Date: